Biotechnology · Healthcare
Board Member
2026-03-23–present
Board Member
Damora Therapeutics, Inc. (DMRA)Equibles does not estimate personal net worth.
Get an email with a short summary when Damora Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DMRA alertsCameron Turtle is recorded as Board Member at Damora Therapeutics, Inc. (DMRA) since March 23, 2026. Damora Therapeutics, Inc. reported in an 8-K filed March 23, 2026 that Cameron Turtle was appointed Board of Directors. Damora Therapeutics, Inc. reported in an 8-K filed March 23, 2026 that Cameron Turtle was appointed Class III director, effective March 23, 2026. Damora Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Damora Therapeutics, Inc. includes Jennifer Jarrett (CEO and Board Member), Sherwin Sattarzadeh (CEO and COO), Peter Harwin (Chairman and Board Member) and 7 others.
“Damora Therapeutics also announced today the appointment of Cameron Turtle, D.Phil., Chief Executive Officer of Spyre Therapeutics, and Mike Landsittel, former Chief Financial Officer of Blueprint Medicines, to the company's Board of Directors.”
“Effective as of March 23, 2026, Michael Landsittel and Cameron Turtle were appointed to the Board as Class III directors.”
2026-03-23–present
Biotechnology · Healthcare
Board Member
2026-03-23–present